Press Releases.

Month Year

Month Year

Investor Alerts

July 18, 2023

Regulus Therapeutics to Present at the H.C. Wainwright 2nd Annual Kidney Conference
June 27, 2023

Regulus Therapeutics Announces First Patient Dosed in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
June 23, 2023

Regulus Therapeutics Announces Appointment of Preston S. Klassen, M.D. to its Board of Directors
June 20, 2023

Regulus Therapeutics Announces Update on Preclinical Studies in Amyotrophic Lateral Sclerosis in Collaboration with Researchers from Harvard's Brigham and Women's Hospital
June 12, 2023

Regulus Therapeutics Strengthens Research & Development Leadership
May 16, 2023

Regulus Therapeutics Advances to Cohort 2 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
May 11, 2023

Regulus Therapeutics Reports First Quarter 2023 Financial Results and Recent Updates
April 13, 2023

Regulus Therapeutics Announces $15 Million Private Placement of Equity
April 12, 2023

Regulus Therapeutics Announces Completion of Enrollment in First Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
March 23, 2023

Regulus Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Recent Updates

Show per page